The median time between the last infusion of anti-CD20 antibody and tumor resample was found to be shorter in the CD20-negative group (2.1 months, IQR: 1.0-5.4) compared with the CD20-positive group (11.5 months, IQR: 7.1-25.3, P = 0.012). Here, MS4A1 is linked to neoplasm.